Subscribe to RSS
DOI: 10.1055/s-2001-18641
Current Options for Injectable Contraception in the United States
Publication History
Publication Date:
29 November 2001 (online)
![](https://www.thieme-connect.de/media/srm/200104/lookinside/thumbnails/10.1055-s-2001-18641-1.jpg)
ABSTRACT
Two injectable forms of hormonal contraception, depot medroxyprogesterone acetate (DMPA, Depo-Provera) and medroxyprogesterone acetate/estradiol cypionate (MPA/E2C, Lunelle), are now available to American women. Both formulations have demonstrated high degrees of efficacy, safety, and ease of use in international and U.S. trials. Data on DMPA have shown a number of noncontraceptive and therapeutic benefits, the most prominent of which is an 80% reduction in the risk of endometrial cancer. Although such benefits are less documented for MPA/E2C, they are expected to be similar to those seen with DMPA and oral contraceptives. Minor side effects of both formulations include menstrual irregularities in the early months of treatment and amenorrhea with DMPA. Patient counseling about the potential for these side effects, as well as possible risks, is important to long-term successful use of these contraceptive methods.
KEYWORD
Injectable contraception - depot medroxyprogesterone acetate - Depo-Provera - medroxyprogesterone acetate - estradiol cypionate - Lunelle
REFERENCES
- 1 Depo-Provera Contraception Injection. Product Information. In: Physicians Desk Reference. 54th ed. Montvale, NJ: Medical Economics Company, Inc.; 2000
- 2 Mishell Jr R D. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med . 1996; 41(suppl) 381-390
- 3 Trussell J, Hatcher R A, Cales Jr W, Stewart F H, Kost K. A guide to interpreting contraceptive efficacy studies. Obstet Gynecol . 1990; 76 558-567
- 4 Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect . 1999; 31 64-93
- 5 World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. Int J Cancer . 1991; 49 186-190
- 6 Schlesselman J J. Risk of endometrial cancer in relation to use of combined oral contraceptives: a practitioner's guide to meta-analysis. Hum Reprod . 1997; 12 1851-1863
- 7 Cullins V E. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. J Reprod Med . 1996 (suppl 5); 41 (428-433)
- 8 Pardthaisong T, Gray R. In utero exposure to steroid contraceptives and outcome of pregnancy. Am J Epidemiol . 1991; 134 795-803
- 9 Lumbiganon P, Rugpao S, Prandha-Fung S. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multinational case-control study. Br J Obstet Gynaecol . 1995; 103 909-914
-
10 American College of Obstetricians and Gynecologists. Uterine leiomyomata. ACOG Technical Bulletin, No
192. Washington, DC: ACOG; 1994
- 11 Muse K. Hormonal manipulation in the treatment of premenstrual syndrome. Clin Obstet Gynecol . 1992; 35 658-666
- 12 Vercellini P, DeGiorgi O, Oldahi S. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol . 1996; 175 396-401
- 13 Kaunitz A M. Injectable contraception. In: Sciarra JJ, Gynecology and Obstetrics Revised ed. Philadelphia, PA: Lippincott Williams & Wilkins 1999: 1-14
- 14 Fraser I S, Dennerstein G J. Depo-Provera use in an Australian metropolitan practice. Med J Aust . 1994; 160 553-556
- 15 Mattson R H, Cramer T A, Caldwell B V. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology . 1984; 34 1255-1258
- 16 DeCeulaer K, Hayes R, Gruber C. Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet . 1982; 2 229-231
- 17 Elkins T E, Gafford L S, Wilks C S. A model clinic approach to the reproductive health concerns of the mentally handicapped. Obstet Gynecol . 1986; 68 185-188
- 18 Schwallie P C, Assenzo J R. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception . 1974; 10 181-202
- 19 World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. Lancet . 1991; 338 833-838
- 20 World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. Contraception . 1992; 45 299-312
- 21 World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. Int J Cancer . 1991; 49 191-195
- 22 Westhoff C. Depot medroxyprogesterone acetate contraception: metabolic parameters and mood changes. J Reprod Med . 1996; 41(suppl) 401-406
- 23 Fraser I S, Weisberg E. A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med J Aust . 1981 (suppl 1); 1 (3-19)
- 24 Black H R, Leppert P, DeCherney A. The effect of medroxyprogesterone acetate on blood pressure. Int J Gynaecol Obstet . 1979; 17 83-87
- 25 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: results of an international, multicenter, case-control study. Contraception . 1998; 57 315-324
- 26 Cundy T, Cornish X, Roberts H. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol . 1998; 92 569-573
- 27 Gbolade B, Ellis S, Murby B. Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol . 1998; 105 790-794
- 28 Paiva L C, Pinto-Neto A M, Faundes A. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception . 1998; 58 351-355
- 29 Scholes D, Lacroix A Z, Ott S M. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol . 1999; 93 233-238
- 30 Tang O S, Tang G, Yip B. Long-term depot-medroxyprogesterone acetate and bone mineral density. Contraception . 1999; 59 25-29
- 31 Bahamondes L, Perrotti M, Castro S. Forearm bone density in users of Depo-Provera as a contraceptive method. Fertil Steril . 1999; 71 849-852
- 32 Naessen T, Olsson S-E, Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception . 1995; 52 35-39
- 33 Taneepanichskul S, Intaraprasert S, Theppisai U. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors. Contraception . 1997; 56 1-3
- 34 Taneepanichskul S, Intaraprasert S, Theppisai U. Bone mineral density during long-term treatment with Norplant implants and depot medroxyprogesterone acetate: a cross-sectional study of Thai women. Contraception . 1997; 56 153-155
- 35 Virutamasen P, Wangsuphachart S, Reinprayoon D. Trabecular bone in long-term depot-medroxyprogesterone acetate users. Asia-Oceania J Obstet Gynaecol . 1994; 20 269-274
- 36 Cundy T, Evans M, Roberts H. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ . 1991; 308 13-16
- 37 Cundy T, Cornish X, Evans M C. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ . 1993; 308 247-248
- 38 Petitti D B, Piaggio G, Mehta S. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol . 2000; 95 736-744
- 39 Orr-Walker B J, Evans M C, Ames R W. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol . 1998; 49 615-618
- 40 Kaunitz A M. Injectable contraception: new and existing options. Obstet Gynecol Clin North Am . 2000; 27 741-780
- 41 Sangi-Haghpeykar H, Poindexter III N A, Bateman L. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol . 1996; 88 227-233
- 42 Kaunitz A M. Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol . 1994; 170 1543-1549
- 43 Paul C, Skegg D CG, Williams S. Depot medroxyprogesterone acetate: patterns of use and reasons for discontinuation. Contraception . 1997; 56 209-214
- 44 Schwallie P C, Assenzo J R. Contraceptive use-efficacy studies utilizing medroxy-progesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril . 1973; 24 331-339
- 45 Espey E, Steinhart J, Ogburn T. Depo-Provera associated weight gain in Navaho women. Contraception . 2000; 62 55-58
- 46 Mainwaring R, Hales H A, Stevenson K. Metabolic parameter, bleeding, and weight changes in US women using progestin only contraceptives. Contraception . 1995; 51 149-153
- 47 Moore L, Valuck R, McDougall C. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception . 1995; 52 215-219
- 48 Taneepanichskul S, Reinprayoon D, Khaosaad P. Comparative study of weight change between long-term DMPA and IUD acceptors. Contraception . 1998; 58 149-151
- 49 Westhoff C, Truman C, Kalmuss D. Depressive symptoms and Depo-Provera. Contraception . 1998; 57 237-240
- 50 Westhoff C, Wieland D, Tiezzi L. Depression in users of depo-medroxyprogesterone acetate. Contraception . 1995; 51 351-354
- 51 Matson S C, Henderson K A, McGrath G J. Physical findings and symptoms of depot medroxyprogesterone acetate use in adolescent females. J Pediatr Adolesc Gynecol . 1997; 10 18-23
- 52 Potter L S, Dalberth B T, Canamar R. Depot medroxyprogesterone acetate pioneers: a retrospective study at a North Carolina health department. Contraception . 1997; 56 305-312
-
53 American College of Obstetricians and Gynecologists. The use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin, No. 18. Washington, DC: ACOG; 2000
- 54 Lunelle Contraception Injection. Product Information. In: Physicians Desk Reference, 54th ed. Montvale, NJ: Medical Economics Company, Inc. 2000
- 55 Kaunitz A M, Garceau R J, Cromie M A. Comparative safety, efficacy, and cycle control of Lunelle™ monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum℗ 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Contraception . 1999; 60 179-187
- 56 Rahimy M H, Ryan K K, Hopkins N K. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile females. Contraception . 1999; 60 209-214
- 57 Rahimy M H, Ryan K K. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile females. Contraception . 1999; 60 189-200
- 58 Bahamondes L, Lavin P, Ojeda G. Return of fertility after discontinuation of the once-a-month injectable contraceptive Cyclofem. Contraception . 1997; 55 307-310
- 59 Zinaman M J, Clegg E D, Brown C C. Estimates of human fertility and pregnancy loss. Fertil Steril . 1996; 65 503-509
- 60 World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation. Comparative study of the effects of two once-a-month injectable steroidal contraceptives (Mesigyna and Cyclofem) on lipid and lipoprotein metabolism. Contraception . 1997; 56 193-207
- 61 Sang G W, Shao Q X, Ge R S. A multicentered phase II comparative clinical trial of Mesigyna, Cyclofem, and injectable No. 1 given by intramuscular injection to Chinese women. Contraception . 1995; 51 185-192
- 62 Newton J R, d'Arcangues C, Hall P E. Once-a-month combined injectable contraceptives. J Obstet Gynaecol . 1994 (suppl 1); 14 (S1-S34)
- 63 Garceau R J, Wajszczuk, Kaunitz A M, and the Lunelle™ Study Group. Bleeding patterns of women using Lunelle™ monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum℗ 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives. Contraception . 2000; 62 289-295
- 64 Hall P E. New once-a-month injectable contraceptives, with particular reference to Cyclofem/Cyclo-Provera. Int J Gynecol Obstet . 1998 (suppl 1); 62 (S43-S56)
- 65 Hall P E, and the Task Force on Introduction and Transfer of Technologies for Fertility Regulation, Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization. The introduction of Cyclofem into family planning programmes: experience from studies in Indonesia, Jamaica, Mexico, Thailand, and Tunisia. Contraception . 1994; 49 489-507